ALNY Alnylam Pharmaceuticals Inc.

77.13
+1.47  (+2%)
Previous Close 75.66
Open 74.7
Price To Book 5.27
Market Cap 7792471513
Shares 101,030,358
Volume 687,080
Short Ratio
Av. Daily Volume 877,426

NewsSee all news

  1. Top 10 Healthcare Stories of 2018
  2. Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma
  3. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019
  4. Alnylam Announces Settlement of Litigation with Silence Therapeutics
  5. Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY)

SEC filingsSee all SEC filings

  1. 8-K - Current report 181227063
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166786
  3. 8-K - Current report 181164790
  4. 8-K - Current report 181116312
  5. 8-K - Current report 181101717

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Dosing to resume later December.
Fitusiran
Hemophilia A and B
Phase 3 positive interim analysis reported September 27, 2018. Full data due mid-2019 with rolling NDA to commence 4Q 2018.
Givosiran
Acute hepatic porphyrias
Phase 3 completion of enrollment announced February 20, 2018 enrollment to be completed 1H 2018. Data 3Q 2019.
Inclisiran - ORION-9
Hypercholesterolemia
Phase 1/2 trial initiated July 2016. Ongoing as of February 2017.
ALN-HBV
Chronic hepatitis B virus (HBV)
Phase 3 data due late-2019.
Lumasiran (ALN-GO1)
Primary Hyperoxaluria Type 1 (PH1)
FDA Approval announced August 10, 2018.
Patisiran
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 trial discontinued October 2016.
Revusiran ENDEAVOUR
ATTR in patients with familial amyloidotic cardiomyopathy (FAC)
Phase 2 data due 2019.
ALN-CC5 (cemdisiran)
IgA nephropathy
Noted September 7, 2017 that Fitusiran program suspended dosing due to fatal thrombotic event. Announced December 15, 2017 that clinical hold has been released. Phase 3 first read-out expected 2H 2019
Fitusiran (ATLAS)
Hemophilia
Phase 3 trial enrolling - noted December 6, 2018.
ALN-TTRsc02 - HELIOS-A
ATTR amyloidosis
Phase 3 enrollment target met - noted March 9, 2018. Data due 3Q 2019.
Inclisiran - ORION-10
Cardiovascular disease (ASCVD)
Phase 3 target enrollment met - noted January 25, 2018. Data due 3Q 2019.
Inclisiran - ORION 11
Cardiovascular disease (ASCVD)
Phase 1/2 data due 2019.
ALN-AAT02
alpha-1 anti-trypsin deficiency-associated liver disease

Latest News

  1. Top 10 Healthcare Stories of 2018
  2. Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma
  3. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019
  4. Alnylam Announces Settlement of Litigation with Silence Therapeutics
  5. Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY)
  6. [$$] Moderna IPO Marks Milestone for New Biotech Market
  7. Moderna’s Rich IPO Valuation Raises the Stakes for Investors
  8. Recent Analysis Shows Microsoft, Alnylam Pharmaceuticals, F5 Networks, Green Plains Partners LP, Itron, and Progress Software Market Influences — Renewed Outlook, Key Drivers of Growth
  9. Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day
  10. Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics
  11. Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis
  12. Alnylam CEO on drug prices: Has to be some type of reward...
  13. Alnylam to Webcast R&D Day
  14. Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate
  15. Why Alnylam Pharmaceuticals Inc’s (NASDAQ:ALNY) CEO Pay Matters To You
  16. DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
  18. DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  19. The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ALNY, CHGG, CWH and DY

SEC Filings

  1. 8-K - Current report 181227063
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166786
  3. 8-K - Current report 181164790
  4. 8-K - Current report 181116312
  5. 8-K - Current report 181101717
  6. CT ORDER - Confidential treatment order 181067399
  7. 8-K - Current report 181026112
  8. 8-K - Current report 181008713
  9. S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments 18989574
  10. S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments 18989543